Evidence map›Paper›PMID 40095960›Full record

ReviewClinical infectious diseases : an official publication of the Infectious Diseases Society of America2025

State-of-the-Art Review: Recurrent Uncomplicated Urinary Tract Infections in Women.

Sonali D Advani, Joshua T Thaden, Reinaldo Perez, Sabrina L Stair, Una J Lee, Nazema Y Siddiqui

Abstract readReview
In one paragraph

Review in Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

17 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Trial
  3. Article
  4. Review
  5. Review
  6. Review
  7. Rapid identification directly from urine using QUICKprep kit.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2026
    Article
  8. IL-17B protects against uropathogenicMicrobiology spectrum · 2026
    Article
  9. Integrative Pharmacokinetic and Metabolomic Profiling ofInternational journal of molecular sciences · 2026
    Article
  10. Efficacy ofClinics and practice · 2026
    Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Review
  17. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Sonali D AdvaniDivision of Infectious Diseases, Department of Medicine, Duke University School of Medicine, Durham, North Carolina, USA.ORCID 0000-0001-5162-6482
Joshua T ThadenDivision of Infectious Diseases, Department of Medicine, Duke University School of Medicine, Durham, North Carolina, USA.
Reinaldo PerezDivision of Infectious Diseases, Department of Medicine, Duke University School of Medicine, Durham, North Carolina, USA.
Sabrina L StairSection of Urology and Renal Transplantation, Virginia Mason Franciscan Health, Seattle, Washington, USA.
Una J LeeSection of Urology and Renal Transplantation, Virginia Mason Franciscan Health, Seattle, Washington, USA.
Nazema Y SiddiquiDivision of Urogynecology and Reconstructive Pelvic Surgery, Department of Obstetrics and Gynecology, Duke University School of Medicine, Durham, North Carolina, USA.

Funding

Resource Core 3 - Metabolomics CoreP30AG028716 · NIA · DUKE UNIVERSITY · PI Sarah B. Peskoe · 2006 to 2026
$24.6M
Duke KURe ProgramK12DK100024 · NIDDK · DUKE UNIVERSITY · PI Cindy Amundsen · 2013 to 2026
$8.4M
Characterization of a Novel E. coli Type III Secretion System Associated with Increased Patient MortalityK08AI171183 · NIAID · DUKE UNIVERSITY · PI Joshua T Thaden · 2022 to 2026
$895k
American Urogynecologic SocietybioMérieuxBoston ScientificCDC HHS 75D30121D12733-D5-E003Duke Claude D. Pepper Older Americans Independence CenterGlaxoSmithKlineInfectious Diseases Society of AmericaLocus BiosciencesNCEZID CDC HHS U54 CK000616NIAID NIH HHS K08 AI171183NIA NIH HHS P30 AG028716NIA NIH HHS P30AG028716NIDDK NIH HHS K12 DK100024NIDDK NIH HHS K12DK100024Society for Healthcare Epidemiology of AmericaSysmex America
6 · The paper itself

Abstract

Over 50% of adult women experience at least 1 urinary tract infection (UTI) in their lifetime, and almost one-quarter of them will experience a recurrent UTI (rUTI). Recurrent UTI is defined as ≥2 UTIs in a 6-month period or ≥3 UTIs in 12 months (at least 1 of these episodes should be culture-proven to confirm infectious etiology). In this narrative review, we discuss the epidemiology, pathogenesis, diagnosis, and treatment considerations for recurrent uncomplicated cystitis in the adult female population. We provide a focused overview of the comprehensive management of these patients, with input from infectious disease physicians, urogynecologists, and urologists with expertise in rUTI, highlighting updated recommendations by the Infectious Diseases Society of America, American Urologic Association, Canadian Urologic Association, and American Urogynecologic Society. Finally, given the variety of prevention strategies, different treatment goals, and the need for "preference sensitive" decisions, we highlight the need for shared decision-making with patients.

Indexed as

Urinary Tract InfectionsAdultAnti-Bacterial AgentsCystitisFemaleHumansRecurrenceAnti-Bacterial Agentsasymptomatic bacteriuriachronic UTILUTSrecurrent cystitisrecurrent UTI

Identifiers

PMID40095960
PMCPMC11912977

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.